Efeitos adversos causados pelo novo esquema de tratamento da tuberculose preconizado pelo ministério da saúde do Brasil;Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian national ministry of health

Jornal Brasileiro de Pneumologia

Volumn 36, Issue 2, 2010, Pages 232-238

  Maciel, Ethel Leonor Noial ^a   Guidoni, Letícia Molino ^a   Favero, Juliana Lopes ^a   Hadad, David Jamil ^a   Molino, Lucilia Pereira ^b   Jonhson, John L ^c   Dietze, Reynaldo ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b Centro de Estudos   (Brazil)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Adverse drug reaction reporting systems; Antitubercular agents; Treatment outcome; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CLASSIFICATION; DRUG COMBINATION; FEMALE; GOVERNMENT; HUMAN; LUNG TUBERCULOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PUBLIC HEALTH; STANDARD; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; BRAZIL; DRUG THERAPY, COMBINATION; FEMALE; GOVERNMENT AGENCIES; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 77953671360     PISSN: 18063713     EISSN: 18063713     Source Type: Journal    
DOI: 10.1590/s1806-37132010000200012     Document Type: Article

References (24)

1. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis. 2002;6(11):995-1000.
2. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology. 1995;21(4):929-32.
3. Oliveira HB, Moreira Filho DC. Treatment abandonment and tuberculosis recurrence: aspects of previous episodes, Brazil, 1993-1994 [Article in Portuguese]. Rev Saude Publica. 2000;34(5):437-43.
4. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978; 117(6): 991-1001
5. Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104(2):151-5.
6. van den Brande P, van Steenbergen W, Vervoort G, Demedts M. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med. 1995;152(5 Pt 1):1705-8.
7. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991;99(2):465-71.
8. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci. 1966;135(2):904-9.
9. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first- line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472-7.
10. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Manual técnico para o controle da tuberculose. Cadernos de atenção básica, no 6. Brasília: Ministério da Saúde, Secretaria de Políticas de Saúde, Departamento de Atenção Básica; 2002.
11. Bisaglia JB. Atualização terapêutica em tuberculose: principais efeitos adversos dos fármacos. Bol Pneumol Sanit. 2003;11(2):53-9.
12. Portal da Saúde. [homepage on the Internet]. Brasília: Ministério da Saúde. [updated 2009 June 16;cited 2009 June 28]. Brasil recebe 1o lote do novo tratamento para tuberculose. Available from: http://portal.saude.gov.br/portal/aplicacoes/noticias/default.cfm?pg=dsp DetalheNoticia&id_area=124&CO_NOTICIA=10602
13. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558-63.
14. Sociedade Brasileira de Pneumologia e Tisiologia. II Consenso Brasileiro de Tuberculose. Diretrizes Brasileiras para Tuberculose 2004. J Bras Pneumol. 2004;30(Suppl 1):S5-S56.
15. Salles CL, Conde MB, Hofer C, Cunha AJ, Calçada AL, Menezes DF, et al. Defaulting from anti-tuberculosis treatment in a teaching hospital in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2004;8(3):318-22.
16. Sociedade Brasileira de Pneumologia e Tisiologia. I Consenso Brasileiro de Tuberculose. J Pneumol. 1997;23(6):281-342.
17. Gonzalez Montaner LJ, Dambrosi A, Manassero M, Dambrosi VM. Adverse effects of antituberculosis drugs causing changes in treatment. Tubercle. 1982;63(4):291-4.
18. Vieira DE, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J Bras Pneumol. 2008;34(12):1049-55.
19. Patel AM, McKeon J. Avoidance and management of adverse reactions to antituberculosis drugs. Drug Saf. 1995;12(1):1-25.
20. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61(9):791-4.
21. Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, Elwood RK, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis. 2007;11(8):868-75.
22. Williams GM, Iatropoulos MJ. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol Pathol. 2002;30(1):41-53.
23. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9(10):2026-30.
24. Bartacek A, Schütt D, Panosch B, Borek M; Rimstar 4-FDC Study Group. Comparison of a four-drug fixed- dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009;13(6):760-6.